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PRL-3 activates mTORC1 in Cancer 
Progression
Zu Ye1,2,*, Abdul Qader Omer Al-aidaroos1,*, Jung Eun Park1,*, Hiu Fung Yuen1, 
Shu Dong Zhang3, Abhishek Gupta1, Youbin Lin1, Han-Ming Shen2 & Qi Zeng1,4
PRL-3, a metastasis-associated phosphatase, is known to exert its oncogenic functions through 
activation of PI3K/Akt, which is a key regulator of the rapamycin-sensitive mTOR complex 1 
(mTORC1), but a coherent link between PRL-3 and activation of mTOR has not yet been formally 
demonstrated. We report a positive correlation between PRL-3 expression and mTOR phospho-
activation in clinical tumour samples and mouse models of cancer and demonstrate that PRL-3 
increased downstream signalling to the mTOR substrates, p70S6K and 4E-BP1, by increasing PI3K/
Akt-mediated activation of Rheb-GTP via TSC2 suppression. We also show that PRL-3 increases 
mTOR translocation to lysosomes via increased mTOR binding affinity to Rag GTPases in an Akt-
independent manner, demonstrating a previously undescribed mechanism of action for PRL-3. 
PRL-3 also enhanced matrix metalloproteinase-2 secretion and cellular invasiveness via activation of 
mTOR, attributes which were sensitive to rapamycin treatment. The downstream effects of PRL-3 
were maintained even under conditions of environmental stress, suggesting that PRL-3 provides a 
strategic survival advantage to tumour cells via its effects on mTOR.
The mechanistic target of rapamycin (mTOR) is a critical regulator of cell growth in response to a vari-
ety of stimuli, including growth factors and nutrients1. mTOR integrates signals from receptor tyrosine 
kinase (RTK)-mediated signalling pathways, such as phosphatidylinositol 3′ -kinase (PI3K)/Akt or extra-
cellular signal-related kinases (ERK), and activates downstream targets to modulate cell growth or cellu-
lar metabolism1. Consistent with its central role in controlling cell growth, the mTOR signalling pathway 
is often hyperactivated in a broad spectrum of human cancers and metabolic diseases2. mTOR forms two 
multiprotein complexes called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), which 
can be distinguished by their specific binding partners, raptor and rictor, respectively, as well as their 
sensitivity to rapamycin: mTORC1 is sensitive and mTORC2 is insensitive3,4. As a master regulator of 
protein synthesis, mTORC1 directly phosphorylates the translational regulators, eukaryotic translation 
initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and p70 S6 kinase (p70S6K). Whereas 4E-BP1 
phosphorylation blocks its inhibitory binding to eIF4E and allows for m7GTP cap-dependent translation 
to proceed, p70S6K phosphorylation promotes the formation of translation initiation complexes and 
enhances mRNA translation5.
Canonical mTOR activation depends on mitogen-driven signalling through PI3K/Akt, although 
non-Akt-dependent activation through the Ras/MEK/ERK pathway has also been described6. The effec-
tor kinases of these pathways directly phosphorylate a heterotrimeric complex consisting of tuberous 
sclerosis 1 (TSC1), TSC2 and TBC1D7, which collectively function as a GTPase-activating protein (GAP) 
for the Rheb (Ras homolog enriched in brain) GTPase7,8. Upon amino acid or serum starvation, TSC1/2 
relocalizes to lysosomes where it induces the conversion of Rheb into its inactive GDP-bound state9,10. 
This results in mTORC1 inhibition, as it is GTP-bound Rheb which directly interacts with mTORC1 
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and strongly stimulates its kinase activity. Furthermore, to be physically activated by GTP-loaded Rheb, 
mTORC1 must also translocate to cellular endomembranes where Rheb is located11. The Rag GTPases, 
members of the Ras family of GTP-binding proteins, are essential for this12. Mechanistically, Ragulator, 
a Rag guanine nucleotide exchange factor, responds to the presence of amino acids by promoting the 
loading of RagA/B with GTP, thereby enabling Rag heterodimers to interact with the raptor component 
of mTORC1 and recruit mTORC1 to lysosomes13,14. Thus, full mTORC1 activation is a two-pronged 
process, requiring growth factor signalling (via PI3K/Akt) to activate Rheb, and mTORC1 translocation 
to Rheb-resident endomembranes, particularly lysosomes11.
Phosphatase of regenerating liver 3 (PRL-3), also known as PTP4A3, is a metastasis-associated pro-
tein, whose expression positively correlates with advanced cancer stages15,16. Through the activation of 
upstream RTKs, PRL-3 enhances cell growth and survival through multiple oncogenic effector pathways, 
including PI3K/Akt, Ras/MAPK, and SRC17–19. PRL-3 has also been shown to increase the activation 
of Akt by the concomitant downregulation in protein expression levels of the main negative regulator 
of PI3K/Akt activity, the phosphatase and tensin homolog (PTEN) phosphatase20. Analysis of cancer 
patient samples reveal a high frequency of PRL-3 expression in tumours but not in paired normal tissues 
of patients21, highlighting the significance of PRL-3 as a marker of poor prognosis in multiple cancer 
types16,22. Therefore, the understanding of the cellular roles of PRL-3 has emerged as a new frontier in 
cancer research.
Given that cells overexpressing PRL-3 exhibit shared characteristics with cells possessing hyperactive 
PI3K/Akt/mTOR signalling, including enhanced cell proliferation, survival, and motility, we hypothe-
sized that PRL-3 might potentially play a role in mTOR regulation, as well in cancer progression. PRL-3 
was shown previously to promote autophagy in ovarian cancers23, a phenomenon typically inhibited by 
mTOR activity24. However, this observation was later shown to be rapamycin-insensitive, discounting 
a role for mTORC1 as a proxy for PRL-3-driven autophagy. Herein, to conclusively address the role of 
mTOR in PRL-3 signalling, we thoroughly examined the correlation of PRL-3 with mTOR activity in: 1) 
human clinical cancer samples, 2) a mouse model of spontaneous mammary tumour development, and 
3) a panel of transgenic tumour cell lines. Collectively, our results uncover a role for oncogenic PRL-3 
signalling via mTORC1 both in vivo and in vitro.
Results
PRL-3 expression correlates with mTOR activity in vivo and in vitro. To investigate the relation-
ship of PRL-3 with mTOR activity, we analysed 12 sets of PRL-3-positive tumours and matched normal 
tissue samples from gastric cancer patients for protein expression levels of PRL-3 and phosphorylation 
status of Thr37/46 of 4E-BP1, a direct substrate/effector of mTOR and indicator of mTOR oncogenic 
activity25. We found that PRL-3 protein was exclusively expressed in tumours but not in any of the 
matched normal samples (Fig. 1a). Notably, 9 out of 12 (75%) PRL-3-expressing tumours also expressed 
higher ratios of phosphorylated 4E-BP1/total 4E-BP1 than their matched PRL-3-negative normal tissue 
samples (asterisks, Fig. 1a). These clinical results implied a possible relationship between PRL-3 expres-
sion levels and mTOR activity in tumour tissues.
We further investigated the above finding in the spontaneous mouse mammary tumour virus (MMTV) 
transgenic model, which harbours the polyomavirus middle T oncoprotein (PyMT) under transcrip-
tional control of the MMTV promoter-enhancer, resulting in the formation of palpable mammary 
tumours in mice as early as 6 weeks of age26. In the MMTV-PyMT system, PyMT is highly expressed 
in mammary tissues at relatively constant levels in heterozygous transgenic adult female mice (Fig. 1b). 
In contrast, endogenous PRL-3 protein expression increases steadily over the same period, specifically 
accumulating at later stages of tumour development (Fig. 1b). This increase in PRL-3 expression during 
mammary tumour development was closely correlated with an increase in levels of both phosphorylated 
4E-BP1 and phosphorylated mTOR on Ser2448, but not total protein expression levels or either (Fig. 1b). 
Ser2448 of mTOR lies within the C-terminal ‘repressor domain’ of mTOR, and its phosphorylation is an 
important marker for activation of the mTOR/4E-BP1 pathway27,28. Collectively, our in vivo observations 
suggested the existence of a correlation between PRL-3 expression levels, mTOR activity, and mTOR 
activation-associated phosphorylation.
PRL-3 was shown previously to promote autophagy in ovarian cancers23, a phenomenon inhibited by 
mTOR activity24. To clarify the apparent discordance between the activation of both mTOR and autophagy 
by PRL-3, we analysed the consequences of overexpressing EGFP-PRL-3 (PRL-3), EGFP-PRL-3-C104S 
(C104S; catalytic-inactive mutant), or empty EGFP vector (Vec) in nine human cancer cell lines from 
diverse cancer types. In six out of the nine cell lines tested, we observed consistent hyperphosphorylation 
of mTOR upon overexpression of PRL-3 (Fig. 1c) but not the catalytic-inactive PRL-3 mutant or vector 
control. However, in three out of nine cell lines, no correlation was observed between PRL-3 expression 
and mTOR phosphorylation (Fig.  1d). Notably, this latter group included A2780 ovarian cancer cells, 
wherein PRL-3 was previously reported to activate autophagy23. Interestingly, rapamycin-mediated inhi-
bition of mTOR failed to abolish the increase in autophagy promoted by PRL-3 in A2780 cells23, indicat-
ing an mTOR-independent route of autophagy activation by PRL-3 in this cell line. Taken together, our 
results suggest that PRL-3 overexpression in multiple cell lines results in mTOR phospho-activation in a 
catalytic-dependent and cell-specific manner.
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Figure 1. PRL-3 expression positively correlates with mTOR activity in vivo and in vitro. (a) Immunoblotting 
of matched pairs of tumour-normal tissues from PRL-3-positive cancer patients. The ratio of phosphorylated/
total 4E-BP1 band densities were calculated and normalized to the phosphorylated/total 4E-BP1 ratio in lane 
1. Asterisks, patient tumour samples wherein 4E-BP1 hyperphosphorylation correlates with PRL-3 expression. 
(b) Immunoblotting of normal and MMTV-PyMT mammary tissues over the course of spontaneous tumour 
development. Top panel, images of normal mice (N) or transgenic MMTV-PyMT mice (T) between the ages 
of 6 to 15 weeks. Middle panel, representative images of excised breast tissues from mice. All images were 
photographed by Thura Min. Blue dashed lines, gross size of palpable mammary tumours in MMTV-PyMT 
mice. Lower panels, correlation between PRL-3 expression and phosphorylation of 4E-BP1 and mTOR. 
(c–d) Overexpression of EGFP vector only (Vec), EGFP-tagged wild-type PRL-3 (PRL-3) or EGFP-tagged 
catalytic-inactive PRL-3 (PRL-3 C104S) in a panel of 9 human cancer cell lines. PRL-3 upregulates mTOR 
phosphorylation in (c) HCT116, HeLa, MCF7, HCT15, LOVO, and SW620 cells, but not in (d) G361, DLD1 or 
A2780 cells. GAPDH served as a loading control. The ratio of phosphorylated/total mTOR band densities were 
calculated and normalized to the phosphorylated/total mTOR ratio in lane 1. Full immunoblots for the cropped 
images presented here are provided in the Supplementary Information.
www.nature.com/scientificreports/
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PRL-3 promotes mTOR activation under normal and stressed cellular conditions via increased 
Akt-TSC2 signalling. The mTOR pathway integrates multiple environmental cues to regulate transla-
tion in response to stress. Deprivation of oxygen or nutrients, particularly amino acids, results in reduced 
mTOR phosphorylation and inhibition of downstream effectors of protein translation, including 4E-BP1 
and p70S6K29,30. mTOR activity is regulated, to a large extent, by the PI3K/Akt pathway and, as such, 
Akt directly phosphorylates TSC2 to relieve its inhibition of mTOR31,32. Since PRL-3 has been reported 
to activate PI3K/Akt signalling33, we first investigated if PRL-3-overexpressing HCT116 cells would dis-
play altered response to hypoxia (oxygen-deprivation) or serum starvation, two environmental stressors 
well-characterized to regulate mTOR activity34. Indeed, HCT116 cells stably overexpressing EGFP-PRL-3 
(PRL-3) had higher levels of phosphorylation of Akt on Ser473, a critical activation site on this kinase35, 
under all conditions tested (Fig. 2a, lanes 2, 5 and 8). This correlated with an increase in phosphorylation 
and inactivation of TSC2, and a corresponding increase in phosphorylation of mTOR and its down-
stream substrates, 4E-BP1 and p70S6K (Fig. 2a, lanes 2, 5 and 8). Next, we investigated whether PRL-
3’s ability to promote mTOR activity remained intact upon amino acid starvation, a potent inhibitory 
stimulus of mTORC1 activity via TSC2-mediated suppression9,10. Remarkably, relative to HCT116-Vec 
or HCT116-C104S cells, HCT116-PRL-3 cells displayed persistent activation of Akt/TSC2/mTOR sign-
aling under this condition (Fig. 2b, lane 5). A similar activation of the Akt-TSC2-Rheb-mTOR-4E-BP1/
p70S6K cascade was also observed in HeLa cells engineered to overexpress PRL-3 (Supplementary Fig. 
1a,b). In a complimentary approach, we used small hairpin RNA (shRNA) constructs to stably deplete 
PRL-3 from HCT116 cells, which express endogenous PRL-3 abundantly. This resulted in reduced phos-
phorylation of Akt, TSC2, mTOR, and its downstream effectors, 4E-BP1 and p70S6K, under all normal 
and stress conditions tested (Fig. 2c, lanes 2, 4, 6, 8, 10).
To validate whether Rheb was involved in PRL-3-mediated TSC2 suppression and activation of 
mTOR, we used a Rheb activation assay to directly study the levels of active Rheb (Rheb-GTP) in PRL-
3-overexpressing cells. Relative to HCT116-Vec or HCT116-C104S cells, Rheb-GTP levels were higher in 
HCT116-PRL-3 cells under basal, hypoxic, or serum starved conditions (Fig. 2d, lanes 2, 5 and 8), as well 
as under amino acid starvation (Fig. 2e, lane 5). Collectively, our results establish a coherent relationship 
between PRL-3 overexpression and increased activity of the canonical Akt/TSC2/Rheb/mTOR signaling 
pathway under both basal and stress conditions (Fig. 2f).
Next, we sought to validate the role of Akt in PRL-3-mediated mTOR hyperactivation using two 
approaches: small interfering RNA (siRNA)-mediated depletion of AKT transcripts, or inhibition of 
Akt kinase using a small-molecule antagonist. siRNA-mediated AKT depletion reduced PRL-3-driven 
phosphorylation of TSC2, mTOR, and its downstream effectors, 4E-BP1 and p70S6K (Fig.  3a, lane 4). 
Likewise, treatment of cells with Akt inhibitor VIII (AktiVIII), a highly potent small-molecule inhibitor 
of Akt1/236, also reduced PRL-3-induced hyperphosphorylation of TSC2, mTOR, 4E-BP1, and p70S6K 
(Fig. 3b, lane 4). However, we noted that HCT116-PRL-3 cells still had higher 4E-BP1 and p70S6K phos-
phorylation relative to HCT116-Vec cells under these treatments, suggesting that Akt inhibition did not 
completely abolish the ability for PRL-3 to enhance S6K and 4E-BP1 phosphorylation. Similar results 
were observed in HeLa cells (Supplementary Fig. 2a,b). Collectively, while these results point to a role 
of Akt-TSC2 signalling in PRL-3-mediated mTOR hyperphosphorylation, the elevated mTOR activity 
despite Akt inhibition hinted at the existence of a secondary, Akt-independent PRL-3-driven mTOR 
activation mechanism.
PRL-3 promotes the relocalisation and accumulation of lysosomal mTOR in an 
Akt-independent, Rag GTPase-dependent manner. Despite a reduction in overall mTOR 
phosphorylation in cells grown under hypoxia, serum deprivation, or amino acid starvation, the PRL-
3-driven increase in phosphorylation of the mTOR substrates 4E-BP1 and p70S6K under each of these 
stressors consistently appeared greater compared to the increase in mTOR S2448 phosphorylation itself 
(Fig.  2a–c, Supplementary Fig. 1a,b). This indirectly suggests that the heightened resistance conferred 
by PRL-3 against mTOR inactivation under limited oxygen or nutrient supply might be due to addi-
tional regulatory mechanism(s) on mTOR. In addition to canonical PI3K/Akt signalling, which regulates 
mTORC1 activity via TSC2-Rheb6, mTORC1 is also tightly regulated by changes to its localisation within 
the cell. In amino acid-starved cells, mTORC1 is rapidly delocalized from lysosomes, effectively inacti-
vating this kinase10. Using colocalization analysis of mTOR with a lysosomal marker, LAMP2, we thus 
investigated if PRL-3 might activate mTOR under amino acid withdrawal by retaining lysosomal mTOR. 
In HCT116-Vec cells, amino acid starvation for 1 h resulted in a loss of mTOR/LAMP2 colocalization 
(Fig. 4a, panel ii). In contrast, mTOR/LAMP2 colocalization, albeit reduced, could still be observed in 
amino acid-starved HCT116-PRL-3 cells (Fig. 4a, panel iv). The ability for PRL-3 to maintain lysosomal 
mTOR accumulation suggested that PRL-3 overexpression might ‘mimic’ amino acid stimulation under 
these conditions, supporting our earlier observation of sustained mTOR signalling activity (Fig.  2b, 
lane 5). To confirm these results, we analyzed the mTOR/LAMP2 colocalization in HCT116 cells stably 
depleted of PRL-3. Depletion of endogenous PRL-3 resulted in a decrease in mTOR/LAMP2 colocali-
zation even under basal, amino acid-replete conditions (Fig. 4b, panel iii), suggesting an important role 
for endogenous PRL-3 in regulating the recruitment/retention of lysosomal mTOR. To further address 
if enhanced PI3K/Akt signalling might account for the increased lysosomal localisation of mTOR, we 
treated HCT116 cells with an Akt inhibitor and analysed mTOR/LAMP2 colocalisation. No change in 
www.nature.com/scientificreports/
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Figure 2. PRL-3-driven mTOR activation correlates with increased Akt-TSC2-Rheb signalling.  
(a) HCT116 cells overexpressing EGFP vector only (Vec), EGFP-tagged wild-type PRL-3 (PRL-3) or EGFP-
tagged catalytic-inactive PRL-3 C104S (C104S) were cultured for 24 h in full media under normoxia (Ctrl), 
hypoxia (Hx), or serum-free (SF) conditions, prior to lysis and western blot analysis with the indicated 
antibodies. (b) HCT116 cells overexpressing Vec, PRL-3 or C104S were cultured for 1 h in full media under 
normoxia (Ctrl) or amino-acid starved (AA-) conditions, prior to analysis as in (a). (c) HCT116 cells stably 
expressing shRNA against PRL-3 (shPRL-3) or control shRNA (shCon) were cultured and analysed as in  
(a). (d) Cell lysates from (a) were immunoprecipitated with a configuration-specific anti-Rheb-GTP antibody 
and analysed by immunoblotting with the indicated antibodies. (e) Cell lysates from (b) were analysed as in 
(d). (f) Proposed signalling pathway for PRL-3 to mTOR substrates, 4EBP1 and p70S6K. Representative full 
immunoblots for the cropped images presented here are provided in the Supplementary Information.
www.nature.com/scientificreports/
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mTOR/LAMP2 colocalization was observed under these conditions (Fig. 4c), suggesting that these phe-
nomenon occurred via a mechanism independent of Akt activity.
The Rag small GTPases have been reported to be critical regulators of mTOR lysosomal relocalisation 
and activation. Upon amino acid stimulation, Rag GTPases associate with mTORC1 as heterodimers, 
recruiting it to late endosomal and lysosomal compartments for subsequent Rheb-mediated activa-
tion12. Rag GTPase heterodimeric complexes (RagB-RagC) were co-expressed in either HCT116-Vec 
or HCT116-PRL-3 cells and binding affinities of Rag GTPases to mTOR, raptor, and rictor were exam-
ined. We found that relative to control cells, PRL-3 overexpression increased the binding affinity of Rag 
GTPase heterodimers to both mTOR and raptor, a component of mTORC1, under basal conditions 
(Fig. 5a, lane 2). Notably, no binding between Rag GTPases and rictor, a component of mTORC2, was 
observed in either cell line (Fig. 5a). Importantly, PRL-3-overexpressing cells maintained strong binding 
of Rag GTPase heterodimers to mTORC1 (mTOR and raptor) persistently under hypoxia, serum-free 
and amino acid-starved conditions (Fig.  5a, lanes 4, 6 and 8). In contrast, HCT116 cells depleted of 
PRL-3 displayed reduced Rag-mTOR-Raptor interaction under all basal and stress conditions tested 
(Fig. 5b, lanes 2, 4, 6 and 8). Collectively, the Rag-mTOR interaction results are in agreement with our 
Figure 3. Akt activity is required for PRL-3-mediated hyperactivation of mTOR signaling. (a) Akt 
in HCT116 cells stably expressing EGFP (Vec) or EGFP-PRL-3 (PRL-3) were transiently depleted using 
scrambled small interfering RNA (siRNA; siCon) or AKT-targeting siRNA (siAKT) and cultured for 48 h 
before analysis of Akt-mTOR pathway activity. The ratio of phosphorylated/total band densities for Akt, 
4E-BP1, and p70S6K were calculated and normalized to their cognate phosphorylated/total protein ratio in 
lane 3. (b) Akt in HCT116 Vec or PRL-3 cells was inhibited for 30 min using Akt inhibitor VIII (AktiVIII) 
before analysis of Akt-mTOR pathway activity as in (a). The ratio of phosphorylated/total band densities 
for Akt, 4E-BP1, and p70S6K were calculated and normalized to their cognate phosphorylated/total protein 
ratio in lane 3. Full immunoblots for the cropped images presented here are provided in the Supplementary 
Information.
www.nature.com/scientificreports/
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observations showing the persistent lysosomal accumulation and elevated mTOR signalling induced by 
PRL-3 under basal and stress conditions.
To test if elevated Rag GTPase activity affected mTOR activity, we collected lysates from cells over-
expressing dominant-negative GST-tagged RagBT54L-RagDQ121L heterodimers9 (RagDN) or empty vector 
(Ctrl) and checked phosphorylation levels of various components of the Akt-mTOR signalling pathway. 
Overexpression of RagDN did not rescue mTOR phosphorylation levels (Fig. 5c, lane 4), despite potently 
blocking the PRL-3-mediated accumulation of mTOR at LAMP2-enriched puncta (Fig.  5d, panel vi). 
However, a reduction in phosphorylation levels of p70S6K and 4E-BP1 was observed, suggesting sup-
pression of mTOR kinase activity and downstream signaling by RagDN (Fig.  5c, lane 4). Notably, no 
Figure 4. PRL-3 promotes the relocalization and accumulation of lysosomal mTOR in an Akt-
independent manner. (a) Immunofluorescence analysis of mTOR and LAMP2 in HCT116 cells 
overexpressing EGFP vector only (Vec) or EGFP-tagged wild-type PRL-3 (PRL-3) cultured in full media 
(Ctrl) or amino-acid starvation media (AA-). Antibodies against human LAMP2 and mTOR were used. Red, 
mTOR signal; green, LAMP2 signal; merge, merged mTOR, LAMP2, and DNA (DAPI) signals. Scale bar, 
10 μ m. A zoomed area within each merged panel enables better visualize mTOR/LAMP2 colocalization. 
(b) HCT116 cells stably expressing small hairpin RNA (shRNA) against PRL-3 (shPRL-3) or control shRNA 
(shCon) were cultured and analysed as in (a). Scale bar, 10 μ m. (c) HCT116 Vec or PRL-3 cells were treated 
with DMSO or Akt Inhibitor VIII (AktiVIII) for 30 min and analyzed by dual immunfluoresence using 
antibodies against mTOR and LAMP2. Red, mTOR signal; green, LAMP2 Scale bar, 10 μ m.
www.nature.com/scientificreports/
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changes in PRL-3-induced phosphorylation of pAkt-S473 was observed upon RagDN expression (Fig. 5c, 
lane 4), in agreement with our earlier data suggesting that Akt lay upstream of mTORC1. Collectively, 
our results show that in parallel and independent of activation of mTOR via the PI3K-Akt-TSC2-Rheb 
pathway, PRL-3 also specifically enhances lysosomal recruitment of mTORC1, but not mTORC2, in a 
Rag-dependent manner.
PRL-3 promotes motility, invasiveness, and MMP-2 secretion in a rapamycin-sensitive manner. 
PRL-3 has been described to promote metastatic development of cancers by increasing both motility 
Figure 5. PRL-3 promotes the accumulation and activation of lysosomal mTOR via increased Rag 
GTPase binding. (a) HCT116-EGFP (Vec) or HCT116-EGFP-PRL-3 (PRL-3) cells were co-transfected with 
GST-RagB/C and cultured under normoxia (Nx, 24 h), hypoxia (Hx, 24 h), serum-free (SF, 24 h), or amino-
acid starved (AA-, 1 h) conditions before GST pull-down and analysis by immunoblotting. Top panel, GST-
enriched fraction; bottom panel, total protein input. (b) HCT116 cells stably expressing small hairpin RNA 
(shRNA) against PRL-3 (shPRL-3) or control shRNA (shCon) were cultured and analysed as in (a).  
(c) Immunoblotting of HCT116-EGFP (Vec) and HCT116-EGFP-PRL-3 (PRL-3) cells overexpressing 
dominant negative RagBT54L-RagDQ121L (RagDN) or vector control (Ctrl). (d) HCT116-Vec or HCT116-PRL-3 
cells were transfected with empty vector (Ctrl) or dominant negative RagBT54L-RagDQ121L (RagDN) for 24 h, 
or starved of amino acid for 1 h, before dual immunfluoresence analysis using antibodies against mTOR and 
LAMP2.The Manders coefficient (colocalization score) for mTOR/LAMP2 signals are given at the bottom 
right corners of panels i-vi. Red, mTOR signal; green, LAMP2. Scale bar, 10 μ m. Full immunoblots for the 
cropped images presented here are provided in the Supplementary Information.
www.nature.com/scientificreports/
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and invasiveness of cancer cells33. In a wound healing assay, PRL-3-overexpressing cells were much more 
motile than control cells, with complete wound closure observed by 48 h (Fig. 6a, panel i-ii). The motility 
of both cell lines could be effectively suppressed by rapamycin treatment (Fig.  6a, panels iii-iv), sug-
gesting a role for mTOR signalling in PRL-3-driven motility. Besides increased motility, the ability of 
disseminating tumour cells to degrade the extracellular matrix (ECM) is an essential property for tumour 
invasion into surrounding tissues. Previously, overexpression of PRL-3 was reported to promote the 
invasiveness of colon cancer cells37 and correlate with clinical hepatocellular carcinoma invasiveness38. In 
agreement with these previous findings, overexpression of PRL-3 significantly increased invasiveness of 
HCT116 cells through a basement matrix relative to control cells (Fig. 6b; p = 5.988E-05). Importantly, 
rapamycin treatment suppressed invasiveness of PRL-3-overexpressing cells to similar levels as the con-
trol cells (Fig.  6b). These results suggest that mTOR is an important mediator of both PRL-3-driven 
motility and invasion.
Matrix metalloproteinases (MMPs) are a group of enzymes which can degrade ECM and activate a 
number of growth factors, thus playing important roles in tumour invasion and metastasis39,40. Notably, 
production of several MMPs are upregulated by increased PI3K/Akt/mTOR activity and are suppressible 
by rapamycin treatment39,40. Since the increased invasiveness of PRL-3-overexpressing cells could be 
suppressed by rapamycin, we analysed these cells in the presence or absence of rapamycin for changes 
in production of MMP-2, which has previously been reported to be regulated by mTOR41,42. Compared 
to control cells, PRL-3-overexpressing cells had higher levels of secreted MMP-2 protein in conditioned 
medium (Fig. 6c). Rapamycin treatment of cells also reduced the secretion of MMP-2 (Fig. 6c), suggest-
ing that PRL-3 was mediating the upregulation of MMP-2 production via increased mTORC1 activity. 
Previously, PRL-3 was reported to upregulate MMP-2 production in an ERK-dependent manner37. Since 
ERK can also activate mTOR via post-translational inactivation of TSC243, we treated cells with U0126, 
an ERK inhibitor, to study if ERK signaling might be involved in PRL-3-mediated mTOR activation. 
Although PRL-3 overexpression resulted in ERK1/2 activation in our system, U0126 treatment did not 
blunt activation of mTOR signaling downstream of PRL-3 (Supplementary Fig. 3a,b), suggesting that 
mTOR hyperactivation by PRL-3 occurs via an ERK-independent pathway.
We further analysed the correlation in gene expression between PRL-3 and MMPs in a publically 
available clinical dataset from colon cancer patients (GSE40967, n = 566). Supporting our in vitro data, 
PRL-3 expression positively correlated with expression of MMP-2 (p = 1.287E-4) Thus, PRL-3 expres-
sion appears to correlate with an mTOR-dependent invasive phenotype characterized by the increased 
expression of MMP-2. Furthermore, in colon cancer patients, MMP-2 expression had prognostic value 
for patient survival when PRL-3 was highly expressed (p = 0.023; Fig.  6d, right panel), but not when 
PRL-3 was expressed at lower levels (p = 0.851; Fig. 6d, left panel), suggesting that the value of MMP-2 
as a prognostic marker might be associated with PRL-3-driven mTOR hyperactivity. Herein, we propose 
a dual-pronged signalling model for PRL-3 activation of mTORC1 via PI3K/Akt and Rag GTPases, cul-
minating in increased motility, invasion, and MMP-2 production by PRL-3-overexpressing cells (Fig. 7).
Discussion
In this study, we found that PRL-3 overexpression induces an aberrant activation of mTOR kinase in 
cancer cells, as reflected by hyperphosphorylation of the direct substrates of mTORC1, 4E-BP1 and 
p70S6K. This phenomenon was more obvious under the stress conditions of oxygen, serum, or amino 
acid deprivation, with sustained mTORC1 activation by PRL-3 despite these growth limitations. We 
formally demonstrate the signalling pathway by which PRL-3 induces mTORC1 activation as via the 
Akt-TSC2-Rheb signalling pathway. Furthermore, we show that PRL-3 also mediates mTORC1 accumu-
lation at lysosomes where it can be activated by Rheb. This latter function of PRL-3 is independent of 
Akt, and is mediated by increased binding affinity of mTOR and raptor to Rag GTPases. Functionally, 
PRL-3-mediated enhancement of mTORC1 signalling resulted in increased motility, invasiveness, and 
MMP-2 secretion. In summary, our findings reveal a novel pathway of PRL-3-mediated cancer invasive-
ness via mTORC1 activation.
In matched tumour-normal patient cancer samples, we observed a striking correlation between PRL-3 
expression and the ratio of phosphorylated/total 4E-BP1, a bona fide readout of PI3K/Akt/mTOR path-
way activity44. Supporting this in vivo observation, increased expression of PRL-3 during tumour pro-
gression in the MMTV-PyMT spontaneous transgenic mouse model was closely mirrored by an increase 
in both mTOR and 4E-BP1 phosphorylation levels. Despite previous studies reporting the association 
between PyMT expression and activation of PI3K/Akt signaling45–47, our results herein indicate that the 
increase in both phosphorylated 4E-BP1 and mTOR levels over the course of PyMT mice development 
more closely mirrored that of PRL-3 expression rather than PyMT strictly. These observations, generated 
from completely different systems, led us to hypothesize about the co-existence of a relationship between 
PRL-3 and mTOR. We validated in vitro that PRL-3 overexpression could induce mTOR phosphorylation 
in six out of the nine human cancer cell lines tested. Notably, this appeared independent of activating 
PIK3CA mutations, since mTOR activation was observed in cells harbouring both wild type (SW620, 
LoVo, HeLa) or mutant (HCT116, MCF7, HCT15) PIK3CA48, suggesting that PRL-3 could enhance 
both basal as well as hyperactivated Akt-mTOR signaling. However, this relationship was not observed 
in a subset of cells, including A2780 ovarian carcinoma cells, wherein we recently showed that PRL-3 
could promote cell proliferation by inducing autophagy23. A possible explanation to interpret this could 
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Figure 6. PRL-3 promotes cancer cell motility, invasiveness, and MMP-2 secretion in a rapamycin-
sensitive manner. (a) Monolayers of HCT116-EGFP (Vec) or HCT116-EGFP-PRL-3 (PRL-3) cells were 
‘wounded’ and monitored over 48 h in the presence or absence of 100 nM rapamycin (Rapa). Dashed lines, 
boundary of cell monolayers on either side of the wound. Scale bar, 100 μ m. (b) The number of invaded 
HCT116-EGFP (Vec) or HCT116-EGFP-PRL-3 (PRL-3) cells through a basement matrix was measured 
by microscopy after culturing in the presence or absence of 100 nM rapamycin. Results are depicted as 
mean ± S.D; ***p = 5.988E-05. (c) The conditioned medium (CM) from HCT116-EGFP (Vec) or HCT116-
EGFP-PRL-3 (PRL-3) cells after culturing in the presence or absence of 100 nM rapamycin for 24 h was 
harvested, concentrated and analysed by immunoblotting. TCL, total cell lysates from matched cell cultures. 
(d) Kaplan-Meier analysis of colorectal cancer patient cohort GSE40967 (n = 557) stratified by low or 
high PRL-3 expression. Full immunoblots for the cropped images presented here are provided in the 
Supplementary Information.
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be that PRL-3 activates autophagy and mTOR independently in different cell lines. Similar findings have 
been reported elsewhere, for example, in luteal cells, activation of ERK1/2 was sufficient for autophagy 
induction without any differential regulation of mTOR activity49.
PRL-3 activates PI3K/Akt signalling via various pathways, including downregulation of phosphatase 
and tensin homologue (PTEN)20 and hyperactivation of receptor tyrosine kinases17. Herein, we char-
acterise mTOR as a novel downstream target of PRL-3 mainly via enhanced PI3K/Akt signalling. 
Surprisingly, PRL-3 also promoted mTOR activation via a parallel increase in Rag GTPase binding and 
lysosomal mTORC1 accumulation. Such PRL-3-driven Rag-GTP accumulation – a principal cause of 
mTORC1 recruitment to lysosomes – occurred in an Akt-independent manner, thereby constituting 
a novel mechanism of mTORC1 regulation distinct from previous mechanistic reports of upstream 
PI3K/Akt activation by PRL-3. This yet-characterized, Akt-independent capacity for PRL-3 to activate 
Rag GTPases might occur via the regulation of Rag activity via the Ragulator complex which, by pro-
moting Rag-GTP formation, has been shown to be necessary for targeting mTORC1 to lysosomes13,14. 
Based on our observations, we propose that PRL-3 functions as a unique mTOR regulator in that it 
both 1) activates Rheb via Akt-TSC2 signaling and, in parallel, 2) promotes recruitment of mTORC1 
to Rheb-resident lysosomes via interaction with Rag proteins, leading to sustained, efficient mTORC1 
activation under basal and stress conditions (Fig. 7). It should be noted that in the comparative studies 
for acute amino acid starvation, we used a nonphysiological condition (incubation in serum-free EBSS) 
which – in addition to a lack of amino acids, also lacks serum, vitamins, and harbours a different salt 
composition from serum-supplemented RPMI-1640 – might affect other signaling pathways than amino 
acid starvation alone would50.
PRL-3-driven mTOR activation, in turn, could promote the metastatic development of cancers in at 
least two ways: increased motility and increased invasiveness. Both these pro-metastatic characteristics 
could be effectively inhibited by treatment with rapamycin, which selectivity inhibits mTORC1 but not 
mTORC2. Because of the importance of mTORC1 in protein translation and cell growth, PRL-3 likely 
exploits mTOR to upregulate the production of proteins involved in motile and invasive behaviour, espe-
cially under stress conditions. Indeed, PRL-3 overexpression resulted in a mTORC1-dependent increase 
in production of oncogenic MMP-2, a collagenase involved in the invasion and metastasis cascade and 
a marker of poor prognosis in multiple cancers51,52. Although a previous report indicates the involve-
ment of integrin beta-1-ERK signalling in PRL-3-mediated upregulation of MMP-237, here we found that 
PRL-3-induced MMP-2 secretion was sensitive to rapamycin-mediated mTORC1 inhibition. A possible 
reconciliation for these observations is that cross-activation between the Ras-MAPK and PI3K-mTORC1 
pathways might co-regulate MMP-2 expression to promote tumour invasiveness. Indeed, activation of 
the RAS-ERK pathway has been shown to lead to mTORC1 activity by increased ERK and RSK signalling 
to the TSC complex53. We hypothesise that by endowing tumour cells with the ability to disseminate 
from unfavourable microenvironments (such as limited nutrient availability and/or limited oxygen) in 
search of more favourable conditions, PRL-3 provides a strategic survival advantage to tumour cells via 
increased PI3K/Akt/mTOR-dependent MMP production and invasiveness.
For decades, mTOR has emerged as an attractive target of anticancer therapy. Our data demonstrate 
an oncogenic role of PRL-3 on mTOR activation in vitro and in vivo, especially under oxygen- and 
nutrient-deprived conditions. Moreover, PRL-3 achieves this unconventionally via regulation of the 
two independent arms of mTORC1 activation, PI3K/Akt-driven Rheb-GTP accumulation, as well as 
Figure 7. Proposed model of PRL-3 activation of mTORC1. PRL-3 activates mTORC1 activity through 
(1) Akt/TSC2/Rheb hyperactivation, and (2) enhanced binding to Rag GTPases and lysosomal recruitment. 
PRL-3-driven mTOR activation ultimately results in increased motility, invasion and MMP-2 secretion of 
cancer cells.
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enhanced Rag GTPase-mediated mTORC1 recruitment to endomembranes for Rheb-mediated activa-
tion. Such pleiotropic regulation by PRL-3 in driving cancer progression cements the urgent need to 
discover novel agents54 targeting this oncogene for better clinical outcomes.
Materials and Methods
Cells and treatments. Human colon cancer cell lines (HCT116, HCT15, LoVo, SW620, DLD-1), 
human cervical cancer cells (HeLa), human melanoma cells (G361), and human breast cancer cells 
(MCF7) were purchased from ATCC (Manassas, VA, USA). Human ovarian cancer cells (A2780) were 
purchased from ECACC (Salisbury, England, United Kingdom). Cell lines expressing EGFP (Vec), 
EGFP-PRL-3 (PRL-3), or EGFP-PRL-3 C104S (PRL-3 C104S) were generated by transfection of cells 
with pEGFP-C1 vector (Clontech, Palo Alto, CA, USA), pEGFP-C1-PRL-3 or pEGFP-C1-PRL-3 (C104S) 
constructs, respectively, using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA), followed by 
G-418 selection (1 mg/mL) for 2 weeks. HCT116 cells stably expressing scrambled or PRL-3-targeting 
shNA constructs (Origene Rockville, MD, USA) were generated by puromycin selection (1 μ g/mL) for 2 
weeks. Cells were grown in RPMI-1640 medium supplemented with 10% FBS (HyClone, Carlsbad, CA, 
USA) and 1% (v/v) penicillin/streptomycin in a humidified incubator at 37 °C with 5% CO2. For serum 
depletion (serum-free; SF) experiments, cells were washed twice in PBS and changed to RPMI-1640 
medium without FBS, supplemented with 1% (v/v) penicillin/streptomycin. For hypoxia experiments, 
cells were placed in a GasPak EZ Gas Pouch (BD Biosciences, Sparks, MD, USA) containing ≤1% O2. 
For amino acid starvation (AA-) experiments, cells were washed twice in PBS, once with Earle’s Balanced 
Salt Solution (EBSS), and finally incubated with EBSS medium for 1 h at 37 °C with 5% CO2. It should be 
noted that compared to RPMI-1640, EBSS not only lacks amino acids, but also lacks vitamins and has a 
different salt composition. For conditioned medium analysis, cells were cultured in RPMI-1640 medium 
without FBS for 24 h and medium was collected and condensed using centrifugal concentrators. Where 
indicated, cells were treated with DMSO-solubilised rapamycin (100 nM final; LC Laboratories, Woburn, 
MA, USA), DMSO-solubilized Akt Inhibitor VIII (5 μ M final; Santa Cruz Biotechnology, Paso Robles, 
CA, USA), or DMSO alone (0.1% final).
Antibodies, plasmids, and siRNA transfection. Antibodies against mTOR (#2983), p-mTOR 
S2448 (#2971), Akt (#4691), p-Akt S473 (#4060), raptor (#2280), 4E-BP1 (#9644), p-4E-BP1 T37/46 
(#2855), p-p70S6K T389 (#9234), TSC2 (#4308), and p-TSC2 S939 (#3615) were purchased from Cell 
Signaling Technologies (Danvers, MA, USA). Anti-p70S6K (#611260) antibody was purchased from 
BD Biosciences (San Jose, CA, USA). Anti-LAMP2 (#ab25631) antibody was purchased from Abcam 
(Cambridge, England, UK). Antibodies against GST (#sc-138) and GFP (sc-9996) were purchased from 
Santa Cruz Biotechnology (Dallas, TX, USA). HRP-conjugated sheep anti-mouse (#515-035-062) and 
goat anti-rabbit (#111-035-045) antibodies were purchased from Jackson ImmunoResearch Laboratories 
Inc. (West Grove, PA, USA), whilst AlexaFluor568-conjugated goat anti-mouse (#A-11004) and 
AlexaFluor633-conjugated goat anti-rabbit (#A-21071) antibodies were from Life Technologies (Grand 
Island, NY, USA). Generation of anti-PRL3 antibody55 and PRL-3-targeting shRNA plasmids17 have 
been reported previously. The pRK5-HA-GST-RagB-WT (#19301), pRK5-HA-GST-RagC-WT (#19304), 
pRK5-HA-GST-RagD-WT (#19307), pRK5-HA GST RagB 54L (#19302), and pRK5-HA GST RagD 121L 
(#19309) constructs were gifts from David Sabatini and sourced from Addgene (Cambridge, MA, USA). 
Expression vectors encoding PRL-3–directed (5′ -TTCTCGGCACCTTAAATTATT-3′ ) or non-targeting 
scrambled shRNA sequences were purchased from OriGene (Rockville, MD, USA). Human AKT-targeting 
(catalogue number 6211S) and control siRNA were from Cell Signaling Technologies. siRNA (100 nM 
final) was transiently transfected using jetPRIME (Polyplus-transfection SA, Illkirch, France) following 
the manufacturer’s recommended protocol.
Western blot analysis. Western blots were performed as described55. Briefly, cells were washed with 
ice-cold PBS and lysed in RIPA buffer containing a cocktail of EDTA-free protease inhibitors (Roche, 
Mannheim, Germany) and phosphatase inhibitors (Nacalai Tesque, Kyoto, Japan). Lysates were clar-
ified by centrifugation (16,000 × g, 10 min) and subjected to western blotting with indicated primary 
antibodies at 1:1,000 dilutions. Species-specific secondary antibodies were used at 1:2,000 dilutions. 
Protein-antibody conjugates were visualized using a chemiluminescent detection kit (Thermo Scientific, 
Waltham, MA, USA), and quantification of band intensities was done using ImageJ software. The ratio 
of phosphorylated/total protein was calculated and normalized as described in the figure legends.
Immunofluorescence analysis. Immunofluorescence analysis was carried out as previously 
described55. Briefly, cells grown on glass coverslips were subjected to various treatments as indicated 
before rinsing with PBS and fixation for 15 min with 4% paraformaldehyde. After rinsing twice with 
PBS, cells were blocked for 1 h in 5% BSA blocking buffer containing 0.1% Triton-X 100, and incubated 
with mouse anti-LAMP2 (1:100) and rabbit anti-mTOR (1:100) antibodies overnight at 4 °C. Coverslips 
were then rinsed three times with PBS and subsequently incubated with secondary antibodies (1:200) 
for 1 h at RT followed by a further three washes in PBS. Coverslips were mounted on glass slides using 
DAPI-containing mounting media and analysed using an LSM700 confocal microscope (Carl Zeiss AG, 
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Jena, Germany). The Manders coefficient (colocalization score) for each image set was calculated using 
the Colocalization tool within ZEN software (Carl Zeiss MicroImaging, Jena, Germany).
In vitro Rag GTPase binding assay. GST-RagB and GST-RagC vectors were co-transfected into 
HCT116-EGFP or HCT116-EGFP-PRL-3 stable cells. The next day, culture media was replaced to incu-
bate cells under normoxia (24 h), hypoxia (24 h), serum-free (24 h), or amino acid-free (1 h) conditions. 
Lysates were harvested, clarified by high speed centrifugation (14 000 × g, 15 min), and incubated with 
glutathione beads overnight at 4 °C with rotation. The beads were washed three times with lysis buffer 
and finally eluted with reduced glutathione (25 mM). Elutes were subjected to western blotting with the 
indicated antibodies.
Rheb activation assay. Analysis of intracellular Rheb-GTP levels was done using a Rheb activa-
tion assay kit (Abcam), according to the manufacturer’s instructions. Briefly, 2.5 × 106 cells, grown under 
the indicated culture conditions, were washed with ice-cold PBS and lysed in kit-supplied lysis buffer 
containing a cocktail of EDTA-free protease inhibitors (Roche). Lysates were clarified by centrifugation 
(16,000 × g, 10 min) before equivalent amounts of lysates (2 mg) were subjected to immunoprecipita-
tion with a configuration-specific monoclonal antibody that specifically recognizes RheB-GTP, but not 
RheB-GDP. Western blotting and densitometry analysis was subsequently used to characterize the pro-
portion of active Rheb (as reflected by the Rheb-GTP/Rheb ratio) present in cellular extracts.
Wound healing assay. 3.5 × 104 HCT116-EGFP or HCT116-EGFP-PRL-3 cells were seeded into 
μ -dishes (Ibidi, Martinsried, Germany) and cultured under normal conditions until they reached conflu-
ence. Subsequently, inserts were removed to yield standardized 500 μ m-wide gaps. ‘Wounded’ cell mon-
olayers were washed in PBS and subsequently cultured in low-serum medium (0.5% FBS) with 100 nM 
rapamycin or 0.1% DMSO for 48 h. Images were acquired sequentially every 24 h using an Axiovert 
200M inverted microscope (Carl Zeiss AG).
Invasion assay. 1 × 104 HCT116-EGFP or HCT116-EGFP-PRL-3 cells were suspended in complete 
medium containing 100 nM rapamycin or 0.1% DMSO and seeded into BioCoat Matrigel invasion cham-
bers with 8.0 μ m PET membranes (Corning, MA, USA). After incubation for 24 h at 37 °C, non-invading 
cells were removed from the upper surface of the membrane by a cotton swab, and membrane inserts 
were washed three times with PBS and fixed in 4% paraformaldehyde for 15 min. Subsequently, mem-
branes were cut, mounted inverted on glass slides, and observed for EGFP fluorescence under an LSM700 
confocal microscope (Carl Zeiss AG). The numbers of invaded cells in four ramdomly-chosen fields were 
counted. Data were presented as mean ± SD of cell number/field and statistically analyzed using the 
Student’s t-test.
Human studies. Human gastric tissue samples were obtained with patient consent from the National 
University Hospital-National University of Singapore (NUH-NUS) Tissue Repository. Experimental pro-
cedures were approved by the Institutional Review Board (IRB) of NUH-NUS for research use and 
conducted in accordance with approved guidelines and regulations.
Analysis of mouse mammary tissues. For the isolation of mammary tissue lysates, the upper-
most pair of mammary glands from wild-type FVB/N mice or MMTV-PyMT mice (at 6, 9, 12, and 15 
weeks) were surgically removed, rinsed in PBS, and homogenised in RIPA lysis buffer using a Polytron 
homogenizer (Luzern, Switzerland) prior to western blot analysis. All animal studies were approved by 
an Institutional Animal Care and Use Committee (IACUC) and were performed in accordance with 
approved guidelines and regulations of the Biological Resource Centre, A*STAR, Singapore.
Gene expression analysis of colon cancer patient dataset. Statistical analyses of the colon 
cancer patient dataset GSE40967 (n = 566) were performed using SPSS 19.0 software (IBM, NY, USA). 
Correlation between PRL-3 and MMP-2, MMP-7, or MMP-9 gene expression was analysed by Spearman 
Correlation. The association between PRL-3 expression and relapse-free survival (RFS) was analysed by 
Kaplan-Meier analysis.
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